References
- Mire-Sluis AR, Barrett YC, Devanarayan V, et al. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J Immunol Methods 2004;289:1–16
- Yelamaggad CV, Shanker G, Ramana Rao RV, et al. Supramolecular helical fluid columns from self-assembly of homomeric dipeptides. Chemistry 2008;14:10462–10471
- Wadhwa M, Skog AL, Bird C, et al. Immunogenicity of granulocyte-macrophage colony-stimulating factor (GM-CSF) products in patients undergoing combination therapy with GM-CSF. Clin Cancer Res 1999;5:1353–1361
- Sesardic D, Mire-Sluis A. Biological standardization and control at the World Health Organization: successes, current issues and future challenges. Biologicals 2000;28:47–53
- Grauer A, Reinel HH, Lunghall S, et al. Formation of neutralizing antibodies after treatment with human calcitonin. Am J Med 1993;95:439–442
- Wadhwa M, Bird C, Fagerberg J, et al. Production of neutralizing granulocyte-macrophage colony-stimulating factor (GM-CSF) antibodies in carcinoma patients following GM-CSF combination therapy. Clin Exp Immunol 1996;104:351–358
- Figlin RA, Itri LM. Anti-interferon antibodies: a perspective. Semin Hematol 1988;25:9–15
- Pachner AR. An improved ELISA for screening for neutralizing anti-IFN-beta antibodies in MS patients. Neurology 2003;61:1444–1446
- Cludts I, Meager A, Thorpe R, et al. Development and characterization of a non-cell-based assay to assess the presence of neutralizing antibodies to interferon-beta in clinical samples. J Immunol Methods 2013;395:37–44
- Kelley M, Cooper C, Matticoli A, et al. The detection of anti-erythropoietin antibodies in human serum and plasma: part II. Validation of a semi-quantitative 3H-thymidine uptake assay for neutralizing antibodies. J Immunol Methods 2005;300:179–191
- Dinarello CA. Interleukin-1 and interleukin-1 antagonism. Blood 1991;77:1627–1652
- Arend WP, Joslin FG, Massoni RJ. Effects of immune complexes on production by human monocytes of interleukin 1 or an interleukin 1 inhibitor. J Immunol 1985;134:3868–3875
- Zanette D, Dundon W, Soffientini A, et al. Human IL-1 receptor antagonist from Escherichia coli: large-scale microbial growth and protein purification. J Biotechnol 1998;64:187–196
- Quartier P, Allantaz F, Cimaz R, et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis 2011;70:747–754
- Cohen SB, Moreland LW, Cush JJ, et al. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann Rheum Dis 2004;63:1062–1068
- Abramson SB, Amin A. Blocking the effects of IL-1 in rheumatoid arthritis protects bone and cartilage. Rheumatology (Oxford) 2002;41:972–980
- Tuo W, Harney JP, Bazer FW. Developmentally regulated expression of interleukin-1 beta by peri-implantation conceptuses in swine. J Reprod Immunol 1996;31:185–198
- Hering D, Thompson W, Hewetson J, et al. Validation of the anthrax lethal toxin neutralization assay. Biologicals 2004;32:17–27
- Hammerling U, Kroon R, Sjodin L. In vitro bioassay with enhanced sensitivity for human granulocyte colony-stimulating factor. J Pharm Biomed Anal 1995;13:9–20
- Lattime EC, Stutman O. WEHI-164 clone 2F: in vitro antitumor effects of tumor necrosis factor and gamma-interferon. Nat Immun 1992;11:34–45
- Dorai H, Sampath TK. Bone morphogenetic protein-7 modulates genes that maintain the vascular smooth muscle cell phenotype in culture. J Bone Joint Surg Am 2001;83:S70–S78